Arvaya Healthcare Authorises Rights Issue Committee for ₹210 Crore Fundraise
Bijoy Hans Ltd · Outcome · 05 Nov 2026, 11:24 pm
Arvaya Healthcare Authorises Rights Issue Committee for ₹210 Crore Fundraise Arvaya Healthcare Limited's board authorised its Rights Issue Committee to finalize, approve, and adopt the Draft Letter of Offer for a proposed Rights Issue of partly paid-up equity shares aggregating up to ₹21,000.00 lakhs (₹210 crore), assuming full subscription. The committee is empowered to file the draft letter with BSE Limited to secure in-principle approval. Final terms, including issue price, rights entitlement ratio, payment schedule, and record date, will be decided and disclosed at a later stage.
Original exchange filing (PDF)
More announcements from Bijoy Hans Ltd
- The investor call arranged by the company on 16th November,2026 was concluded successfully. Please find attached herewith Audio for the same. · 17 Nov 2026
- Investor Presentation in relation with the Unaudited Standalone and consolidated Financial Results of the Company for the quarter and half year ended on September 30 2026 and overall company .... · 16 Nov 2026
- Unaudited Standalone and Consolidated financial results for the quarter ended 30th September 2026 · 14 Nov 2026
- Statement of Deviation and Variation for the quarter ended 30th September 2026 is not applicable to the Company. · 14 Nov 2026
- Declaration of Unaudited standalone and consolidated Financial Results for the half year ended and 2nd quarter ended 30th September 2026 · 14 Nov 2026
- Revision in intimation and In compliance with the provisions of Regulation 30 of SEBI (LODR) Regulations 2015, we would like to inform you that Arvaya Healthcare Limited (formerly known .... · 16 Nov 2026
- In compliance with the provisions of Regulation 30 of SEBI (LODR) Regulations 2015, we would like to inform you that Arvaya Healthcare Limited (formerly known as Bijoy Hans Limited) (''the .... · 16 Nov 2026
- Arvaya Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve Pursuant to the provisions .... · 13 Nov 2026
